JP2002513037A - Ｆｉｚｚタンパク質 - Google Patents

Ｆｉｚｚタンパク質

Info

Publication number
JP2002513037A
JP2002513037A JP2000546012A JP2000546012A JP2002513037A JP 2002513037 A JP2002513037 A JP 2002513037A JP 2000546012 A JP2000546012 A JP 2000546012A JP 2000546012 A JP2000546012 A JP 2000546012A JP 2002513037 A JP2002513037 A JP 2002513037A
Authority
JP
Japan
Prior art keywords
fizz
cells
seq
polypeptide
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2000546012A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002513037A5 (enExample
Inventor
エル． ガーニー，オースティン
ヘベール，キャロライン
ジェー． ヘンゼル，ウィルアム
カバコフ，ローナ
エル． シェルトン，デイビッド
ビー． タマス，ダニエル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of JP2002513037A publication Critical patent/JP2002513037A/ja
Publication of JP2002513037A5 publication Critical patent/JP2002513037A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2000546012A 1998-04-24 1999-04-20 Ｆｉｚｚタンパク質 Withdrawn JP2002513037A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US8299998P 1998-04-24 1998-04-24
US60/082,999 1998-04-24
US8514998P 1998-05-12 1998-05-12
US60/085,149 1998-05-12
US10026398P 1998-09-14 1998-09-14
US60/100,263 1998-09-14
PCT/US1999/008615 WO1999055868A2 (en) 1998-04-24 1999-04-20 Fizz proteins

Publications (2)

Publication Number Publication Date
JP2002513037A true JP2002513037A (ja) 2002-05-08
JP2002513037A5 JP2002513037A5 (enExample) 2006-06-29

Family

ID=27374384

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000546012A Withdrawn JP2002513037A (ja) 1998-04-24 1999-04-20 Ｆｉｚｚタンパク質

Country Status (7)

Country Link
US (1) US20040018980A1 (enExample)
EP (1) EP1071772A2 (enExample)
JP (1) JP2002513037A (enExample)
AU (1) AU769166B2 (enExample)
CA (1) CA2326001A1 (enExample)
IL (1) IL139219A0 (enExample)
WO (1) WO1999055868A2 (enExample)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7344880B2 (en) 1998-04-24 2008-03-18 Genentech, Inc. Nucleic acid encoding PRO9912 polypeptides
AU4834999A (en) 1998-06-26 2000-01-17 Incyte Pharmaceuticals, Inc. Human signal peptide-containing proteins
US7282570B2 (en) 1999-04-20 2007-10-16 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
ATE525390T1 (de) * 1999-04-27 2011-10-15 Univ Pennsylvania Verwendung von resistin spezifischen antikörpern in der behandlung von diabetes
EP1234036A2 (en) * 1999-11-30 2002-08-28 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US7307153B2 (en) 1999-12-23 2007-12-11 Genentech, Inc. Antibodies that bind PRO9912
EP1248803B1 (en) * 2000-01-12 2010-05-05 Yale University Nogo receptor-mediated blockade of axonal growth
US7164001B2 (en) 2000-01-20 2007-01-16 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US6677119B2 (en) 2000-04-28 2004-01-13 Florida Atlantic University Methods of detecting a colon cancer cell
DE10105592A1 (de) * 2001-02-06 2002-08-08 Achim Goepferich Platzhalter zur Arzneistofffreigabe in der Stirnhöhle
US7109302B1 (en) 2002-04-01 2006-09-19 Human Genome Sciences, Inc. Antibodies that specifically bind to GMAD
AU2003224720A1 (en) * 2002-04-08 2003-10-27 Eli Lilly And Company Use of resistin to treat hematopoietic disorders
US8317816B2 (en) 2002-09-30 2012-11-27 Acclarent, Inc. Balloon catheters and methods for treating paranasal sinuses
EP1596926A2 (en) 2003-02-07 2005-11-23 The Johns Hopkins University Hypoxia induced mitogenic factor
CA2550117A1 (en) * 2003-12-16 2005-06-30 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
US20190314620A1 (en) 2004-04-21 2019-10-17 Acclarent, Inc. Apparatus and methods for dilating and modifying ostia of paranasal sinuses and other intranasal or paranasal structures
US20070208252A1 (en) * 2004-04-21 2007-09-06 Acclarent, Inc. Systems and methods for performing image guided procedures within the ear, nose, throat and paranasal sinuses
US7559925B2 (en) * 2006-09-15 2009-07-14 Acclarent Inc. Methods and devices for facilitating visualization in a surgical environment
US7361168B2 (en) 2004-04-21 2008-04-22 Acclarent, Inc. Implantable device and methods for delivering drugs and other substances to treat sinusitis and other disorders
US10188413B1 (en) 2004-04-21 2019-01-29 Acclarent, Inc. Deflectable guide catheters and related methods
US8702626B1 (en) 2004-04-21 2014-04-22 Acclarent, Inc. Guidewires for performing image guided procedures
US8864787B2 (en) 2004-04-21 2014-10-21 Acclarent, Inc. Ethmoidotomy system and implantable spacer devices having therapeutic substance delivery capability for treatment of paranasal sinusitis
US9399121B2 (en) 2004-04-21 2016-07-26 Acclarent, Inc. Systems and methods for transnasal dilation of passageways in the ear, nose or throat
US7803150B2 (en) 2004-04-21 2010-09-28 Acclarent, Inc. Devices, systems and methods useable for treating sinusitis
US9101384B2 (en) * 2004-04-21 2015-08-11 Acclarent, Inc. Devices, systems and methods for diagnosing and treating sinusitis and other disorders of the ears, Nose and/or throat
US8764729B2 (en) * 2004-04-21 2014-07-01 Acclarent, Inc. Frontal sinus spacer
US8747389B2 (en) 2004-04-21 2014-06-10 Acclarent, Inc. Systems for treating disorders of the ear, nose and throat
US7410480B2 (en) * 2004-04-21 2008-08-12 Acclarent, Inc. Devices and methods for delivering therapeutic substances for the treatment of sinusitis and other disorders
US8932276B1 (en) 2004-04-21 2015-01-13 Acclarent, Inc. Shapeable guide catheters and related methods
US9554691B2 (en) * 2004-04-21 2017-01-31 Acclarent, Inc. Endoscopic methods and devices for transnasal procedures
US20070167682A1 (en) 2004-04-21 2007-07-19 Acclarent, Inc. Endoscopic methods and devices for transnasal procedures
US7419497B2 (en) * 2004-04-21 2008-09-02 Acclarent, Inc. Methods for treating ethmoid disease
US20060063973A1 (en) 2004-04-21 2006-03-23 Acclarent, Inc. Methods and apparatus for treating disorders of the ear, nose and throat
US20060004323A1 (en) 2004-04-21 2006-01-05 Exploramed Nc1, Inc. Apparatus and methods for dilating and modifying ostia of paranasal sinuses and other intranasal or paranasal structures
US8146400B2 (en) 2004-04-21 2012-04-03 Acclarent, Inc. Endoscopic methods and devices for transnasal procedures
US8894614B2 (en) 2004-04-21 2014-11-25 Acclarent, Inc. Devices, systems and methods useable for treating frontal sinusitis
US7654997B2 (en) * 2004-04-21 2010-02-02 Acclarent, Inc. Devices, systems and methods for diagnosing and treating sinusitus and other disorders of the ears, nose and/or throat
US7462175B2 (en) 2004-04-21 2008-12-09 Acclarent, Inc. Devices, systems and methods for treating disorders of the ear, nose and throat
US9089258B2 (en) * 2004-04-21 2015-07-28 Acclarent, Inc. Endoscopic methods and devices for transnasal procedures
US9351750B2 (en) 2004-04-21 2016-05-31 Acclarent, Inc. Devices and methods for treating maxillary sinus disease
US8951225B2 (en) 2005-06-10 2015-02-10 Acclarent, Inc. Catheters with non-removable guide members useable for treatment of sinusitis
US8114113B2 (en) * 2005-09-23 2012-02-14 Acclarent, Inc. Multi-conduit balloon catheter
US20070179518A1 (en) * 2006-02-02 2007-08-02 Becker Bruce B Balloon Catheters and Methods for Treating Paranasal Sinuses
US8190389B2 (en) 2006-05-17 2012-05-29 Acclarent, Inc. Adapter for attaching electromagnetic image guidance components to a medical device
US9820688B2 (en) 2006-09-15 2017-11-21 Acclarent, Inc. Sinus illumination lightwire device
US8343491B2 (en) 2006-12-18 2013-01-01 The Johns Hopkins University Anti-HIMF antibodies to treat lung diseases
US8439687B1 (en) 2006-12-29 2013-05-14 Acclarent, Inc. Apparatus and method for simulated insertion and positioning of guidewares and other interventional devices
US8118757B2 (en) 2007-04-30 2012-02-21 Acclarent, Inc. Methods and devices for ostium measurement
US8485199B2 (en) 2007-05-08 2013-07-16 Acclarent, Inc. Methods and devices for protecting nasal turbinate during surgery
US20090030409A1 (en) * 2007-07-27 2009-01-29 Eric Goldfarb Methods and devices for facilitating visualization in a surgical environment
US10206821B2 (en) 2007-12-20 2019-02-19 Acclarent, Inc. Eustachian tube dilation balloon with ventilation path
US8182432B2 (en) 2008-03-10 2012-05-22 Acclarent, Inc. Corewire design and construction for medical devices
WO2009134917A2 (en) * 2008-04-29 2009-11-05 Wyeth Methods for treating inflammation
EP2306886B1 (en) 2008-07-30 2018-10-31 Acclarent, Inc. Paranasal ostium finder devices
MX2011003025A (es) 2008-09-18 2011-04-21 Acclarent Inc Metodos y aparatos para tratar trastornos otorrinolaringologicos.
US20100241155A1 (en) 2009-03-20 2010-09-23 Acclarent, Inc. Guide system with suction
US8435290B2 (en) 2009-03-31 2013-05-07 Acclarent, Inc. System and method for treatment of non-ventilating middle ear by providing a gas pathway through the nasopharynx
US7978742B1 (en) 2010-03-24 2011-07-12 Corning Incorporated Methods for operating diode lasers
US20110160740A1 (en) * 2009-12-28 2011-06-30 Acclarent, Inc. Tissue Removal in The Paranasal Sinus and Nasal Cavity
US9155492B2 (en) 2010-09-24 2015-10-13 Acclarent, Inc. Sinus illumination lightwire device
US10503373B2 (en) * 2012-03-14 2019-12-10 Sony Interactive Entertainment LLC Visual feedback for highlight-driven gesture user interfaces
US9629684B2 (en) 2013-03-15 2017-04-25 Acclarent, Inc. Apparatus and method for treatment of ethmoid sinusitis
US9433437B2 (en) 2013-03-15 2016-09-06 Acclarent, Inc. Apparatus and method for treatment of ethmoid sinusitis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3695295A (en) * 1995-10-25 1997-05-15 Queen's University At Kingston Neurotrophin antagonists
AU7962398A (en) * 1997-06-19 1999-01-04 Schering Corporation Mammalian genes; related reagents
US20020111476A1 (en) * 1997-06-19 2002-08-15 Karin Franz-Bacon Mammalian genes; related reagents
AU9130498A (en) * 1997-09-05 1999-03-22 Human Genome Sciences, Inc. 50 human secreted proteins
WO1999031236A2 (en) * 1997-12-17 1999-06-24 Genset EXTENDED cDNAs FOR SECRETED PROTEINS

Also Published As

Publication number Publication date
WO1999055868A3 (en) 2000-11-09
EP1071772A2 (en) 2001-01-31
AU769166B2 (en) 2004-01-15
US20040018980A1 (en) 2004-01-29
CA2326001A1 (en) 1999-11-04
IL139219A0 (en) 2001-11-25
WO1999055868A2 (en) 1999-11-04
AU3654799A (en) 1999-11-16

Similar Documents

Publication Publication Date Title
JP2002513037A (ja) Ｆｉｚｚタンパク質
CA2188017C (en) Cardiotrophin and uses therefor
US20060147945A1 (en) Novel secreted proteins and their uses
US20030215913A1 (en) Nucleic acids, vectors, host cells, polypeptides, and uses thereof
JP2003159083A (ja) 新規な神経栄養因子
EP1309614A2 (en) Novel secreted proteins and their uses
PT1887014E (pt) Homëlogos de toll humana
US20040038242A1 (en) Novel secreted proteins and their uses
JP2011155971A (ja) Ｉｌ−１関連ポリペプチド
US20020164702A1 (en) Novel tyrosine kinase receptors and ligands
AU758011B2 (en) Persephin and related growth factors
JP4671371B2 (ja) 脊椎動物Ｓｍｏｏｔｈｅｎｅｄタンパク質
US20050048483A1 (en) Novel secreted proteins and their uses
KR20010085816A (ko) 면역 관련 질환 치료용 조성물 및 치료 방법
WO2002048361A2 (en) Novel secreted proteins and their uses
EP1313765A2 (en) Secreted proteins and methods of using same
US20030212258A1 (en) Novel secreted proteins and methods of using same
US20040265970A1 (en) Don-1 gene and polypeptides and uses therefor
US6716600B1 (en) Persephin and related growth factors
US6967245B2 (en) Ucp5
US7342102B2 (en) Uncoupling protein 5 (UCP5)
US20040215007A1 (en) Novel secreted proteins and their uses
JP2002526075A (ja) Ｕｃｐ４
EP1500663A1 (en) Secreted proteins and their uses
JP2002533062A5 (enExample)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060420

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060420

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060424

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060425

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20070420